Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Associations of DMT therapies with COVID-19 severity in multiple sclerosis

View ORCID ProfileSteve Simpson-Yap, Edward De Brouwer, View ORCID ProfileTomas Kalincik, Nick Rijke, Jan Hillert, Clare Walton, Gilles Edan, Yves Moreau, Tim Spelman, Lotte Geys, Tina Parciak, Clément Gautrais, Nikola Lazovski, Ashkan Pirmani, Amin Ardeshirdavani, Lars Forsberg, Anna Glaser, Robert McBurney, Hollie Schmidt, Arnfin Bergmann, Stefan Braune, Alexander Stahmann, Rodden Middleton, Amber Salter, Robert J. Fox, Anneke van der Walt, Helmut Butzkueven, Raed Al-Roughani, Serkan Ozakbas, Juan I Rojas, Ingrid van der Mei, Nupur Nag, Rumen Ivanov, Guilherme Sciascia do Olival, Alice Estavo Dias, Melinda Magyari, Doralina Guimarães Brum, Maria Fernanda Mendes, Ricardo Alonso, Richard Nicholas, Johana Bauer, Anibal Chertcoff, Ana Zabalza, Georgina Arrambide, Alexander Fidao, Giancarlo Comi, Liesbet M. Peeters
doi: https://doi.org/10.1101/2021.02.08.21251316
Steve Simpson-Yap
1CORe, Department of Medicine, The University of Melbourne, Australia
2Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Australia
3Menzies Institute for Medical Research, University of Tasmania, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steve Simpson-Yap
Edward De Brouwer
4ESAT-STADIUS, KU Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas Kalincik
1CORe, Department of Medicine, The University of Melbourne, Australia
5Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tomas Kalincik
Nick Rijke
6MS International Federation, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Hillert
7Department of Clinical Neuroscience, Swedish MS Registry, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clare Walton
6MS International Federation, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Edan
8Department of Neurology, CHU Pontchaillou, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Moreau
4ESAT-STADIUS, KU Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Spelman
7Department of Clinical Neuroscience, Swedish MS Registry, Sweden
9Karolinska Institutet, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lotte Geys
10Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina Parciak
10Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium
11Department of Medical Informatics, University Medical Center Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clément Gautrais
12Department of Computer Science and AI, KU Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikola Lazovski
13QMENTA, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashkan Pirmani
4ESAT-STADIUS, KU Leuven, Belgium
10Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amin Ardeshirdavani
4ESAT-STADIUS, KU Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Forsberg
7Department of Clinical Neuroscience, Swedish MS Registry, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Glaser
9Karolinska Institutet, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert McBurney
14iConquerMS People-Powered Research Network, Accelerated Cure Project for MS, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hollie Schmidt
14iConquerMS People-Powered Research Network, Accelerated Cure Project for MS, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnfin Bergmann
15NeuroTransData Study Group, NeuroTransData, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Braune
15NeuroTransData Study Group, NeuroTransData, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Stahmann
16German MS-Register by the National MS Society, MS Forschungs- und Projektentwicklungs-gGmbH, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodden Middleton
17UK MS Register, Swansea University, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amber Salter
18COViMS, United States of America
19Division of Biostatistics, Washington University in St Louis, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Fox
18COViMS, United States of America
20Mellen Center for Multiple Sclerosis, Cleveland Clinic, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anneke van der Walt
21Department of Neuroscience, Central Clinical School, Monash University, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helmut Butzkueven
21Department of Neuroscience, Central Clinical School, Monash University, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raed Al-Roughani
22Dokuz Eylul University, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serkan Ozakbas
23Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan I Rojas
24Neurology Department, Hospital Universitario de CEMIC, Argentina
25RELACOEM, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid van der Mei
26The Australian MS Longitudinal Study, Menzies Institute for Medical Research, University of Tasmania, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nupur Nag
2Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rumen Ivanov
27Bulgarian SmartMS COVID-19 Dataset, Bulgaria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guilherme Sciascia do Olival
28ABEM - Brazilian MS Patients Association, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Estavo Dias
28ABEM - Brazilian MS Patients Association, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melinda Magyari
29The Danish Multiple Sclerosis Registry, Departement of Neurology, University Hospital Rigshospitalet, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doralina Guimarães Brum
30Universidade Estadual Paulista, Unesp, Faculdade de Medicina, Botucatu, Brazil
31REDONE.br – Brazilian Registry of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Fernanda Mendes
31REDONE.br – Brazilian Registry of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders, Brazil
32Irmandade da Santa Casa de Misericórdia de São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo Alonso
25RELACOEM, Argentina
33Multiple Sclerosis University Center, Ramos Mejia Hospital – EMA, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Nicholas
17UK MS Register, Swansea University, United Kingdom
34Imperial College London, United Kingdom
35Swansea University, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johana Bauer
36Mental Health Area, EMA, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anibal Chertcoff
37MS and Demyelinating Diseases. Hospital Británico de Buenos Aires, EMA, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Zabalza
38Servei de Neurologia-Neuroimmunologia. Centre d’Esclerosi Múltiple de Catalunya, (Cemcat). Vall d’Hebron Institut de Recerca, Vall d’Hebron Hospital Universitari. Universitat Autònoma de Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgina Arrambide
38Servei de Neurologia-Neuroimmunologia. Centre d’Esclerosi Múltiple de Catalunya, (Cemcat). Vall d’Hebron Institut de Recerca, Vall d’Hebron Hospital Universitari. Universitat Autònoma de Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Fidao
2Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giancarlo Comi
39Institute of Experimental Neurology, Ospedale San Raffaele, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liesbet M. Peeters
10Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: liesbet.peeters@uhasselt.be
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background People with multiple sclerosis (MS) are a vulnerable group for severe COVID-19, particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS.

Methods Data from 12 data-sources in 28 countries were aggregated. Demographic and clinical covariates were queried, alongside COVID-19 clinical severity outcomes, hospitalisation, admission to ICU, requiring artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression.

Results 657 (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analysed. Older age, progressive MS-phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalisation (aOR=1.56,95%CI=1.01-2.41; aOR=2.43,95%CI=1.48-4.02) and ICU admission (aOR=2.30,95%CI=0.98-5.39; aOR=3.93,95%CI=1.56-9.89), though only rituximab was associated with higher risk of artificial ventilation (aOR=4.00,95%CI=1.54-10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalisation (aOR=1.75,95%CI=1.29-2.38; aOR=2.76,95%CI=1.87-4.07) and ICU admission (aOR=2.55,95%CI=1.49-4.36; aOR=4.32,95%CI=2.27-8.23) but only rituximab with artificial ventilation (aOR=6.15,95%CI=3.09-12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalisation (aOR=1.86,95%CI=1.13-3.07; aOR=2.88,95%CI=1.68-4.92) and ICU admission (aOR=2.13,95%CI=0.85-5.35; aOR=3.23,95%CI=1.17-8.91), but only rituximab with ventilation (aOR=5.52,95%CI=1.71-17.84). Importantly, associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death.

Conclusions Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalisation, ICU admission, and requiring artificial ventilation, and ocrelizumab with hospitalisation and ICU admission, suggesting their use may be a risk factor for more severe COVID-19.

Competing Interest Statement

TK has served on scientific advisory boards for Roche, Sanofi-Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi-Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi-Genzyme, Teva, BioCSL and Merck and received research support from Biogen. NR % CW have no personal pecuniary interests to disclose, other than being an employee of MSIF, which receives income from a range of corporate sponsors, recently including: Biogen, BristolMyersSquibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis, Roche. JH has received honoraria for serving on advisory boards for Biogen, Celgene, Sanofi-Genzyme, Merck KGaA, Novartis and Sandoz and speakers fees from Biogen, Novartis, Merck KGaA, Teva and Sanofi-Genzyme, has served as principal investigator for projects, or received unrestricted research support from Biogen, Celgene, Merck KGaA, Novartis, Roche and Sanofi-Genzyme, and his MS research was funded by the Swedish Research Council and the Swedish Brain foundation. GE has received consulting/speaking fees and research support from Bayer, Novartis, Teva, Sanofi Genzyme, Merck Serono, Biogen Idec, and Roche. TS has served on scientific advisory boards for Biogen. RMcB & HS, work for the Accelerated Cure Project for MS (ACP), which has received grants, collaboration funding, payments for use of assets, or in-kind contributions from the following companies: EMD Serono, Sanofi/Genzyme, Biogen, Genentech, AbbVie, Octave, GlycoMinds, Pfizer, MedDay, AstraZeneca, Teva, Mallinckrodt, MSDx, Regeneron Genetics Center, BC Platforms, and Celgene. ACP has also received funding from the Patient-Centered Outcomes Research Institute (PCORI) and the National MS Society (NMSS). AG has received research support from Novartis. RMcB. has received consulting payments from EMD Serono, which have been donated to ACP. AB has received consulting fees from and is an advisory board/speaker/other activities for NeuroTransData, and has worked on project management/clinical studies for and received travel expenses from Novartis and Servier. AS has no personal pecuniary interests to disclose, other than being the lead of the German MS-Registry, which receives (project) funding from a range of public and corporate sponsors, recently including The German Innovation Fund (G-BA), The German MS Trust, Biogen, German MS Society, Celgene (BMS), Merck, Novartis, Roche, and Sanofi. RM has received no personal funding from any sources, but works for the UK MS Register which is funded by the UK MS Society and has received funding for specific projects from Novartis, Sanofi-Genzyme and Merck KGaA. RJF has received personal consulting fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, Sanofi, Teva, and TG Therapeutics, and has served on advisory committees for Actelion, Biogen, Immunic, and Novartis, and received clinical trial contract and research grant funding from Biogen and Novartis. AvdW has received honoraria and unrestricted research funding from Novartis, Biogen, Roche, Merck and Sanofi. HB receives compensation for Advisory Board, Steering Committee and Educational activities from Biogen, Roche, Merck, and Novartis. His institution receives research support from Roche, Novartis, Biogen, NHMRC and MRFF Australia, MS Research Australia and the Trish MS Foundation. He receives personal compensation from Oxford HPF for serving on the steering group of MS Brain Health. RA-R received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche and Sanofi-Genzyme. JIR has received honoraria from Novartis as a scientific advisor, and has received travel grants and attended courses and conferences on behalf of Merck-Serono Argentina, Novartis Argentina. GSdO has received honoraria for lecturing and support for congress participation from Biogen, Merck, Novartis, Sanofi/Genzyme, EMS and Roche. MM has served on scientific advisory board for Biogen, Sanofi, Roche, Novartis, Merck, Abbvie, has received honoraria for lecturing from Biogen, Merck, Novartis, Sanofi, Genzyme, and has received research support and support for congress participation from Biogen, Genzyme, Roche, Merck, Novartis. RA has received honoraria from Novartis as a scientific advisor, travel grants and attended courses and conferences on behalf of Merck-Serono Argentina, Biogen Argentina, Genzyme Argentina, Roche Argentina and Novartis Argentina. RN has received honoraria from Novartis, Roche and Biogen for advisory boards. AZ has received travel expenses for scientific meetings from Biogen, Novartis, and Genzyme, speaking honoraria from Eisai, and a study grant from Novartis. GA has received compensation for consulting services or participation in advisory boards from Sanofi, Merck and Roche; research support from Novartis; travel expenses for scientific meetings from Novartis, Roche, Stendhal, and ECTRIMS; speaking honoraria from Sanofi and Merck; and is a member of the International Women in Multiple Sclerosis (iWiMS) network executive committee. GC has received consulting and speaking fees from Novartis, Teva Pharmaceutical Industries Ltd, Teva Italia Srl, Sanofi Genzyme, Genzyme Corporation, Genzyme Europe, Merck KGgA, Merck Serono SpA, Celgene Group, Biogen Idec, Biogen Italia Srl, F. Hoffman-La Roche, Roche SpA, Almirall SpA, Forward Pharma, Medday and Excemed. LMP has no personal pecuniary interests to disclose, other than being the chair of The MS Data Alliance (MSDA), which receives income from a range of corporate sponsors, recently including Biogen, BristolMyersSquibb (formerly Celgene), Canopy Growth Corporation, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, Roche. SSY, EDB, YM, LG, TP, CG, NL, AP, AA, LEF, SB, AS, SO, IvDM, NN, RI, AED, DG, MFM, JB, AF, and AC have no conflicts of interests to disclose.

Funding Statement

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The operational costs linked to this study are funded by the Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA), acting under the umbrella of the European Charcot Foundation (ECF). The MSDA receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Canopy Growth Corporation, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix and Roche. MSIF receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis and Roche. This work was supported by the Flemish Government under the Onderzoeksprogramma Artificiele Intelligentie (AI) Vlaanderen programme and the Research Foundation Fladers (FWO) for ELIXIR Belgium Flanders (FWO) for ELIXIR Belgium. The central platform was provided by QMENTA and the computational resources used in this work were provided by Amazon.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the ethical committee of Hasselt University [CME2020/025]. Individual data-sources obtained additional ethics approval as required.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Persons interested in acquiring the data used for this analysis may contact Professor Dr Liesbet Peeters in regards.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 10, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Associations of DMT therapies with COVID-19 severity in multiple sclerosis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Associations of DMT therapies with COVID-19 severity in multiple sclerosis
Steve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, Nick Rijke, Jan Hillert, Clare Walton, Gilles Edan, Yves Moreau, Tim Spelman, Lotte Geys, Tina Parciak, Clément Gautrais, Nikola Lazovski, Ashkan Pirmani, Amin Ardeshirdavani, Lars Forsberg, Anna Glaser, Robert McBurney, Hollie Schmidt, Arnfin Bergmann, Stefan Braune, Alexander Stahmann, Rodden Middleton, Amber Salter, Robert J. Fox, Anneke van der Walt, Helmut Butzkueven, Raed Al-Roughani, Serkan Ozakbas, Juan I Rojas, Ingrid van der Mei, Nupur Nag, Rumen Ivanov, Guilherme Sciascia do Olival, Alice Estavo Dias, Melinda Magyari, Doralina Guimarães Brum, Maria Fernanda Mendes, Ricardo Alonso, Richard Nicholas, Johana Bauer, Anibal Chertcoff, Ana Zabalza, Georgina Arrambide, Alexander Fidao, Giancarlo Comi, Liesbet M. Peeters
medRxiv 2021.02.08.21251316; doi: https://doi.org/10.1101/2021.02.08.21251316
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Associations of DMT therapies with COVID-19 severity in multiple sclerosis
Steve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, Nick Rijke, Jan Hillert, Clare Walton, Gilles Edan, Yves Moreau, Tim Spelman, Lotte Geys, Tina Parciak, Clément Gautrais, Nikola Lazovski, Ashkan Pirmani, Amin Ardeshirdavani, Lars Forsberg, Anna Glaser, Robert McBurney, Hollie Schmidt, Arnfin Bergmann, Stefan Braune, Alexander Stahmann, Rodden Middleton, Amber Salter, Robert J. Fox, Anneke van der Walt, Helmut Butzkueven, Raed Al-Roughani, Serkan Ozakbas, Juan I Rojas, Ingrid van der Mei, Nupur Nag, Rumen Ivanov, Guilherme Sciascia do Olival, Alice Estavo Dias, Melinda Magyari, Doralina Guimarães Brum, Maria Fernanda Mendes, Ricardo Alonso, Richard Nicholas, Johana Bauer, Anibal Chertcoff, Ana Zabalza, Georgina Arrambide, Alexander Fidao, Giancarlo Comi, Liesbet M. Peeters
medRxiv 2021.02.08.21251316; doi: https://doi.org/10.1101/2021.02.08.21251316

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (941)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8967)
  • Forensic Medicine (4)
  • Gastroenterology (417)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1321)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10765)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1817)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4107)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (361)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)